Light Therapy Devices in Ophthalmology and Dermatology - Vietnam Registration 230002670/PCBB-HCM
Access comprehensive regulatory information for Light Therapy Devices in Ophthalmology and Dermatology in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại B medical device is registered under number 230002670/PCBB-HCM and manufactured by Theo theo phụ lục.
This page provides complete technical specifications, regulatory compliance details, 1 companies making similar products including Espansione Marketing S.p.A., and 1 recent registrations in the same category. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.
Device Details
Registration Details
230002670/PCBB-HCM
000.00.19.H29-231004-0028
Theo theo phụ lục
Theo phụ lục
Technical Details
-EYE-LIGHT System is designed to treat certain clinical conditions in the field of ophthalmology, particularly those of a recurrent nature or related to dermatology. -Specifically, the EYE-LIGHT System utilizes the IPL - OPE® (multi-spectrum light therapy) and LLLT - LED LIGHT MODULATION® (monochromatic biostimulating light - LED) technologies and is indicated for the following treatments: IPL (OPE®) 600 – 1200nm It stimulates the secretion of lipids in the tear film of the patient, using the selective photothermal principle. The target cells in the affected area of the basal layer absorb the light energy, which is then converted into heat energy, causing localized warming. It is suitable for treating disorders of the meibomian glands (MGD), acne (pimples), and Sjogren's syndrome, when combined with red LLLT therapy. LLLT - Red LED 625 nm It activates the endogenous heating process of the skin, and particularly of the eyelids, through the emission of LED light. The energy of the red light stimulates reactions at the cellular level, increasing ATP (adenosine triphosphate) production and the activity of fibroblasts, thereby activating anti-inflammatory effects and stimulating the cellular mechanisms responsible for tissue repair and regeneration. It is indicated for treating disorders of the meibomian glands (MGD) and for treating chalazion (blocked meibomian gland), when combined with red LLLT therapy; It is indicated for treating chalazion (blocked meibomian gland) when used alone; It is indicated for treating blepharitis, acne (pimples), and Demodex-related dermatitis, when combined with green LLLT therapy; It is indicated for treating post-surgical eyelid conditions (ptosis, ectropion) and AMD (Age-related Macular Degeneration), when combined with yellow LLLT therapy.
Dates and Status
Nov 29, 2023

